The prothrombin-consumption test described by one of us in 1947 1 was based on the assumption that the amount of prothrombin remaining in serum when blood clotted under standardized conditions was a measure of the thromboplastin that resulted from the interaction of platelets with a plasma constituent which was designated as thromboplastinogen. It was concluded that the poor consumption of prothrombin observed when hemophilic blood clotted was caused by a lack of this plasma factor and that, therefore, the method could be employed for its assay. This assumption was supported by the significant increase in prothrombin consumption obtained after giving a hemophiliac a transfusion of normal blood or plasma. In mild hemophilia, however, the results were not always consistent, and, peculiarly, it was observed that when the platelet-rich plasma of such patients was clotted the prothrombin consumption was lower and more constant than when the test was done on whole
QUICK AJ, HUSSEY CV. Hemophilia: Quantitative Studies of the Coagulation Defect: A Modified Prothrombin-Consumption Test Using Erythrocytin. AMA Arch Intern Med. 1956;97(5):524–531. doi:10.1001/archinte.1956.00250230018002
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: